Health Care • Biotechnology: Pharmaceutical Preparations
$2.12 ▲ +0.02
(+0.95%)
MKT CAP: $5.0M • VOL: 34.5K
52W L $2 52W H $5
ROARABLE / RQD
D • 47/100
PIOTROSKI
4 / 9
XBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.0M | $2.5M | $2.5M |
| YoY Revenue Growth % | +19.0% | -1.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.8M | -$4.2M | -$4.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$2.7M | -$4.0M | -$4.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$2.3M | -$2.8M | -$4.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$2.3M | -$2.8M | -$4.1M |
| FCF Margin % | -76.8% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -30.3% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.4M | $6.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XBIO.